Potassium%25252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an electrolyte replacement used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. ## Adult Dosing * **Oral:** Dosing is individualized based on serum potassium levels and clinical status. * **Prevention:** Typically 20 mEq once daily or divided twice daily. * **Treatment:** May range from 20 mEq to 100 mEq per day, divided into 2-5 doses. Maximum recommended daily dose is generally 100-120 mEq/day. Sustained-release formulations are often preferred to minimize gastrointestinal adverse effects. * **Intravenous (IV):** Dosing is highly individualized and depends on the severity of hypokalemia and the patient's clinical condition. * **Mild hypokalemia (serum K+ 3.0-3.4 mEq/L):** Typically 10-20 mEq infused over several hours. * **Moderate hypokalemia (serum K+ 2.5-2.9 mEq/L):** Typically 20-40 mEq infused over several hours. * **Severe hypokalemia (serum K+ <2.5 mEq/L) or ECG changes:** Dosing is more aggressive and often guided by central venous access and continuous cardiac monitoring. Doses may range from 40-80 mEq or higher, administered via peripheral or central line, with infusion rates generally not exceeding 10-20 mEq/hour for peripheral administration and up to 40 mEq/hour (with cardiac monitoring) for central administration. **Maximum infusion rate and concentration for IV KCL are critical safety considerations and often dictated by local protocol and available access.** ## Pediatric Dosing * Dosing is individualized based on age, weight, serum potassium levels, and clinical condition. * **Oral:** Daily maintenance doses typically range from 1-3 mEq/kg/day, not to exceed adult maximums. * **Intravenous (IV):** Dosing is highly individualized. Doses up to 0.5-1 mEq/kg per dose, not exceeding 10-20 mEq per dose, are common for mild to moderate hypokalemia. Infusion rates for IV KCL should generally not exceed 0.5-1 mEq/kg/hour or 20 mEq/hour, whichever is less, especially in neonates and infants, due to risk of cardiotoxicity. **Concentration limits for IV KCL administration are crucial and vary by age and access route (peripheral vs. central); consult institutional guidelines.** ## Dose Adjustments * No specific dose adjustment is typically required for hepatic impairment. * Renal impairment: Use with extreme caution. Dosing needs to be significantly reduced and carefully monitored due to impaired potassium excretion. ## Contraindications * Hyperkalemia. * Conditions which may predispose to hyperkalemia, such as Addison's disease, untreated Addison's disease, severe renal impairment, untreated adrenal insufficiency, systemic acidosis, and certain chronic renal conditions. * Anuria, oliguria, or progressive renal failure. * Gastrointestinal obstruction or delayed gastric emptying. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain, flatulence. * **Serious:** Hyperkalemia (muscle weakness, fatigue, paralysis, cardiac arrhythmias, cardiac arrest), gastrointestinal ulceration, bleeding, perforation, and obstruction (especially with sustained-release oral formulations). Esophageal or gastric irritation. Phlebitis and pain at the IV injection site. ## Key Drug Interactions * **ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene), Aldosterone antagonists (e.g., eplerenone):** Increased risk of hyperkalemia. * **NSAIDs:** May increase serum potassium levels and reduce the effectiveness of potassium supplements. * **Digitalis glycosides:** Hyperkalemia may potentiate digitalis toxicity; hypokalemia may increase digitalis toxicity. * **Neuromuscular blocking agents:** Effects may be altered by changes in serum potassium. ## Monitoring * Serum potassium levels (frequently, especially with IV administration, rapid dose changes, or in patients with renal impairment). * Renal function (BUN, creatinine). * ECG (especially with IV administration or severe hypokalemia). * Signs and symptoms of hyperkalemia and hypokalemia. * For oral formulations: gastrointestinal tolerance. ## Clinical Pearls * Oral potassium chloride should generally be taken with meals or a full glass of water to minimize gastrointestinal irritation. * IV potassium chloride is a high-alert medication and must be administered carefully, with attention to infusion rate, concentration, and patient monitoring to prevent fatal hyperkalemia. Never administer IV push. * The presence of hypokalemia can potentiate digitalis toxicity. * The management of severe hypokalemia, especially with ECG changes or significant cardiac compromise, requires close medical supervision, often in an intensive care setting. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional protocols before making clinical decisions.